Home › Metastatic Cancer › NCT06174987

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Signed informed consent form, prior to the start of any study-specific qualification procedures and willing to comply with all study requirements.
* Currently enrolled in a DS or DS/AZ-sponsored parent study that has met EOS definition.
* No evidence of progressive disease and determined to have investigator-assessed clinical benefit from continued treatment with a DS or DS/AZ alliance study drug(s).

Exclusion Criteria:

* Participants with any unresolved/ongoing AE(s) that meets the study drug discontinuation criteria
* Participant who has been off T-DXd therapy for \>18 weeks (126 days) between the last dose from the parent study and the initiation of study drug administration on this study

About the study

This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).

What is being tested

• T-DXd (drug)

Sponsor: Daiichi Sankyo · Participants: 50 · Started: Jan 5, 2024

Contact the study team

• Daiichi Sankyo Contact for Clinical Trial Information · Phone: 908-992-6400

Official record on ClinicalTrials.gov — NCT06174987

Locations in the U.S.

Conditions

• Metastatic Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.